Exodus Point Capital Management, LP Day One Biopharmaceuticals, Inc. Transaction History

Exodus Point Capital Management, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$12.03 - $17.69 $995,458 - $1.46 Million	-82,748 Reduced 84.76%	14,873 $205,000
Q1 2024 May 14, 2024	SELL	$13.56 - $17.46 $1.72 Million - $2.22 Million	-126,988 Reduced 56.54%	97,621 $1.61 Million
Q3 2023 Nov 09, 2023	BUY	$11.22 - $14.86 $419,897 - $556,120	37,424 Added 19.99%	224,609 $2.76 Million
Q2 2023 Aug 10, 2023	BUY	$11.74 - $14.47 $2.2 Million - $2.71 Million	187,185 New	187,185 $2.24 Million
Q4 2022 Feb 13, 2023	BUY	$18.77 - $22.0 $995,298 - $1.17 Million	53,026 Added 410.96%	65,929 $1.42 Million
Q3 2022 Nov 10, 2022	SELL	$16.44 - $26.57 $166,044 - $268,357	-10,100 Reduced 43.91%	12,903 $258,000
Q2 2022 Aug 19, 2022	BUY	$5.72 - $17.9 $131,577 - $411,753	23,003 New	23,003 $412,000
Q3 2021 Nov 15, 2021	SELL	$20.0 - $27.92 $187,440 - $261,666	-9,372 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$19.0 - $23.69 $178,068 - $222,022	9,372 New	9,372 $213,000

178

84M

144K

218K

Ticker DAWN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,461,104
Market Cap $924M
Description
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.